Patricia Eshaghian, MD
Pulmonary Disease · Los Angeles, CANPI 1114191186
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Vertex at 59.9% of the total. 2025 is the largest year on record at $14,902, 3.0 times the $4,928 reported in 2019. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $586.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$15K
- GSK$8K
- Insmed, Inc.$487
- Gilead$258
- Breathe Technologies, Inc.$225
- Inspire Medical Systems, Inc.$200
- plus $507 from 7 others
What the payments were for
- Consulting fees$13,32054%
- Speaking & faculty fees$8,97036%
- Food & beverage$2,2989%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 8 | $14,749 |
| GSK | 14 | $8,202 |
| Insmed, Inc. | 6 | $487 |
| Gilead | 3 | $258 |
| Breathe Technologies, Inc. | 2 | $225 |
| Inspire Medical Systems, Inc. | 1 | $200 |
| Mylan Specialty L.p. | 2 | $134 |
| Alcresta Therapeutics, Inc. | 1 | $129 |
| Pharming Healthcare, Inc. | 1 | $121 |
| Shionogi Inc | 1 | $76 |
| AbbVie | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,630 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 105 | $2,633,738 |
| CresembaIsavuconazonium Sulfate | 30 | $193,734 |
| CaystonAztreonam Lysine | 11 | $120,179 |
| ZenpepLipase/Protease/Amylase | 16 | $113,934 |
| Spiriva RespimatTiotropium Bromide | 85 | $74,360 |
| CreonLipase/Protease/Amylase | 14 | $69,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $69,657 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 82 | $48,807 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $28,603 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $18,840 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $16,524 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,684 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $12,248 |
| AlvescoCiclesonide | 13 | $8,813 |
| BreynaBudesonide/Formoterol Fumarate | 36 | $7,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $14,749 | $2,633,738105 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $8,202 | $121,435154 claims |
| GileadCayston | $258 | $120,17911 claims |
| AbbVieCreon | $19 | $69,74914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$1.3M
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
- Igor BarjaktarevicLos Angeles$337K
- Scott OhLos Angeles$252K
- Christopher CooperLos Angeles$239K
- John BelperioLos Angeles$224K
- Robert StrieterLos Angeles$173K
- Roy ArtalLos Angeles$152K
- Donald TashkinLos Angeles$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.